tradingkey.logo
tradingkey.logo
Search

Abbvie Announces Updated Results From Phase 2 Epcore® Nhl-6 Study Evaluating The Potential For Outpatient Monitoring Of Epcoritamab In Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (Dlbcl)

ReutersSep 3, 2025 12:32 PM
facebooktwitterlinkedin

- Abbvie Inc ABBV.N:

  • ABBVIE ANNOUNCES UPDATED RESULTS FROM PHASE 2 EPCORE® NHL-6 STUDY EVALUATING THE POTENTIAL FOR OUTPATIENT MONITORING OF EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL)

  • ABBVIE INC - STUDY SHOWS CONSISTENT CRS AND ICANS INCIDENCE WITH PREVIOUS STUDIES

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI